N@N

Cubist Pharmaceuticals to Host Product Pipeline Investor and Analyst Event

^{Published on 2010-09-13 10:10:46 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that it will host an Investor Event at the NASDAQ MarketSite, Times Square, New York City at 9:00 a.m. ET on Monday, September 20^th, 2010. Due to space constraints, on-site attendance is limited to invited guests only, but any and all investors may aattenda via the live webcast. Click [ here ] or go to [ http://tinyurl.com/34pqjyx ] to register for the webcast.

Presentations will focus on the scientific background for and the progress being made in the development of Cubist's most advanced pipeline programs:

• The Phase 2 candidate CXA-201, a potent, bactericidal, I.V. antibiotic in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and
• The Phase 2 candidate CB-183,315, a potent, oral, bactericidal lipopeptide in development for the treatment of Clostridium difficile-associated diarrhea

In addition, the company will provide market-based perspective on growth factors supporting the continued historic growth trajectory for CUBICIN® (daptomycin for injection). Also, the company will provide an overview of its discovery and pre-clinical programs.

The event archive will be accessible at [ www.cubist.com ] in the Investor Relations Calendar section for 30 days following the event.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program, added with Cubista™s acquisition of Calixa Therapeutics Inc. in December 2009, focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea); and a Phase 1 program intended to address the unmet medical need for a treatment for serious infections caused by MDR Gram-negative pathogens. Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.